If you have been reading about dual agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
==== Neonatal hypoglycemia ==== Low blood sugar may occur in healthy neonates aged less than 48 hours who have not eaten for a few hours. During the 48-hour neonatal period, the neonate adjusts glucagon and epinephrine levels following birth, which may trigger transient hypoglycemia. In children who are aged greater than 48 hours, serum glucose on average ranges from 70 to 100 mg/dL (3.9–5.5 mmol/L), similar to adults, with hypoglycemia being far less common.
== Human uses == The royal angelfish is considered to be harmless to humans, and has minor commercial use in the aquarium industry. It is valued by aquarium hobbyists for being one of the few "reef safe" angelfish as its diet is composed primarily of sponges, and does not include corals.
== Epidemiology == Diabulimia is most common in women, and in people between 15 and 30 years old. Around 40% of men with type 1 diabetes may have skipped insulin injection at least once, and around 20% of women. Some studies have found that up to 60% of people with type 1 diabetes deliberately restrict insulin at some point. Many articles and studies further conclude that diabetic females have, on average, higher body mass index (BMI) than their nondiabetic counterparts. Girls and young adult women with higher BMIs are also shown to be more likely to have disordered eating behavior (DEB). Many authoritative articles show that preteen and teenage girls with type 1 diabetes have significantly higher rates of eating disorders of all types than do girls without diabetes.
Sources: en.wikipedia.org
=== 1981 === January 17: Martial law was lifted by Ferdinand Marcos in preparation for the visit of Pope John Paul II. January 20: Ronald Reagan inaugurated 40th President of the United States. Reagan is elected on a platform opposed to the concessions of détente. Also that day the Iran hostage crisis ends. March 30: Two months after his inauguration Ronald Reagan is shot in the chest while leaving a Washington hotel. The gunman, John Hinckley, is found to be mentally unhinged and obsessed with actress Jodie Foster. April 1: The United States suspends economic aid to Nicaragua. April 6: The Somaliland War of Independence was waged by the Somali National Movement in northern Somalia. May 13: While riding in an open-topped car through the Vatican, Pope John Paul II is shot four times in the abdomen and right arm. The gunman, Mehmet Ali Agca, is a Turkish Kurd with uncertain motives. August 19: Gulf of Sidra Incident: Libyan planes attack U.S. jets in the Gulf of Sidra, which Libya has illegally annexed. Two Libyan jets are shot down; no American losses are suffered. September 21: Belize becomes independent from the UK. 1,500 British soldiers remain to deter Guatemala from attacking the country over territorial disputes. October 6: President Anwar Sadat of Egypt is shot and killed in Cairo during the annual victory parade. October 27: A Soviet submarine, the U137, runs aground not far from the Swedish naval base at Karlskrona. November 23: The U.S. Central Intelligence Agency (CIA) begins to support anti-Sandinista Contras. December 13: Gen.
Dent, London, 1981) ISBN 978-0-460-04535-3 Is Life an Astronomical Phenomenon? (University College Cardiff Press, 1982) ISBN 9780906449493 Why Neo-Darwinism Does Not Work (with Fred Hoyle) (University College Cardiff Press, 1982) ISBN 9780906449509 Proofs that Life is Cosmic (with Fred Hoyle) (Institute of Fundamental Studies, Sri Lanka, Memoirs no.1, 1982) From Grains to Bacteria (with Fred Hoyle) (University College Cardiff Press, 1984) ISBN 9780906449646 Fundamental Studies and the Future of Science (ed.) (University College Cardiff Press, 1984) ISBN 9780906449578 Living Comets (with Fred Hoyle) (University College Cardiff Press, 1985) ISBN 9780906449790 Archaeopteryx, the Primordial Bird: A Case of Fossil Forgery (with Fred Hoyle) (Christopher Davies, Swansea, 1986) ISBN 9780715406656 The Theory of Cosmic Grains (with Fred Hoyle) (Kluwer, Dordrecht, 1991) ISBN 9780792311898 Life on Mars? The Case for a Cosmic Heritage (with Fred Hoyle) (Clinical Press, Bristol, 1997) ISBN 9781854570413 Astronomical Origins of Life: Steps towards Panspermia (with Fred Hoyle) (Kluwer, Dordrecht, 2000) ISBN 9780792360810 Cosmic Dragons: Life and Death on Our Planet (Souvenir Press, London, 2001) ISBN 9780285636064 Fred Hoyle's Universe (ed. with G. Burbidge and J. Narlikar) (Kluwer, Dordrecht, 2003) ISBN 9781402014154 A Journey with Fred Hoyle (World Scientific, Singapore, 2005) ISBN 9789812565792 Comets and the Origin of Life (with J. Wickramasinghe and W.
== Awards == Royal Society of Western Australia, University Medal for outstanding student in natural and earth sciences (2003) Society of Environmental Toxicology and Chemistry, Best Platform Presentation by a student (2008) FNR ATTRACT Fellowship for the development of new methods to identify unknown chemicals (2018) The Analytical Scientist, Top 40 under 40 Power List (2018) The Analytical Scientist Power List, "Planet Protectors" field (2024)
During an interview for Al Jazeera television on 17 November 2005, he said his election as MP earlier in the year was "despite all the efforts made by the British government, the Zionist movement and the newspapers and news media which are controlled by Zionism". In Trials of the Diaspora: A History of Anti-Semitism in England, Anthony Julius cites this interview as one example of Galloway pandering to the antisemitic prejudices of his audience. According to Julius, Galloway merely refers to the "right-wing press" in the British media, whereas he has the habit of adding the word "Zionist" when speaking on television in the Arab world. A few years later, in a May 2009 speech given at a meeting in Westminster, Galloway said: "I do not agree with the argument that there is a shadowy Jewish influence. Israel is doing what America wants it to do and to argue otherwise is to go down the dark tunnel of racist antisemitism". Galloway criticised the British government's support of Israel during the Gaza war and condemned the genocide of Palestinians in the Gaza Strip. Galloway disputed reports from the Israeli government about the October 7 attacks. Specifically, he disputed the number of babies killed and suggested two-thirds of those killed were from the IDF. He also suggested that those who propagate the official Israeli government account of 7 October are "war criminals". The Board of Deputies of British Jews, the largest Jewish community organisation in the UK, has called Galloway "a demagogue and conspiracy theorist".
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
它属于合成修饰肽，同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂，与选择性 GLP-1 激动剂在靶点范围上不同。